234 related articles for article (PubMed ID: 27696256)
41. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.
Cremer FW; Kartal M; Hose D; Bila J; Buck I; Bellos F; Raab MS; Brough M; Moebus A; Hager HD; Goldschmidt H; Moos M; Bartram CR; Jauch A
Cancer Genet Cytogenet; 2005 Sep; 161(2):116-24. PubMed ID: 16102581
[TBL] [Abstract][Full Text] [Related]
42. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
43. The genetic architecture of multiple myeloma.
Prideaux SM; Conway O'Brien E; Chevassut TJ
Adv Hematol; 2014; 2014():864058. PubMed ID: 24803933
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
Bolli N; Biancon G; Moarii M; Gimondi S; Li Y; de Philippis C; Maura F; Sathiaseelan V; Tai YT; Mudie L; O'Meara S; Raine K; Teague JW; Butler AP; Carniti C; Gerstung M; Bagratuni T; Kastritis E; Dimopoulos M; Corradini P; Anderson KC; Moreau P; Minvielle S; Campbell PJ; Papaemmanuil E; Avet-Loiseau H; Munshi NC
Leukemia; 2018 Dec; 32(12):2604-2616. PubMed ID: 29789651
[TBL] [Abstract][Full Text] [Related]
45. [Classification and genetic abnormalities of multiple myeloma].
Hanamura I; Iida S
Nihon Rinsho; 2015 Jan; 73(1):17-27. PubMed ID: 25626298
[TBL] [Abstract][Full Text] [Related]
46. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
Lange K; Gadzicki D; Schlegelberger B; Göhring G
Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
[TBL] [Abstract][Full Text] [Related]
47. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
[TBL] [Abstract][Full Text] [Related]
48. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Bolli N; Avet-Loiseau H; Wedge DC; Van Loo P; Alexandrov LB; Martincorena I; Dawson KJ; Iorio F; Nik-Zainal S; Bignell GR; Hinton JW; Li Y; Tubio JM; McLaren S; O' Meara S; Butler AP; Teague JW; Mudie L; Anderson E; Rashid N; Tai YT; Shammas MA; Sperling AS; Fulciniti M; Richardson PG; Parmigiani G; Magrangeas F; Minvielle S; Moreau P; Attal M; Facon T; Futreal PA; Anderson KC; Campbell PJ; Munshi NC
Nat Commun; 2014; 5():2997. PubMed ID: 24429703
[TBL] [Abstract][Full Text] [Related]
49. Chromosome translocations in multiple myeloma.
Bergsagel PL; Kuehl WM
Oncogene; 2001 Sep; 20(40):5611-22. PubMed ID: 11607813
[TBL] [Abstract][Full Text] [Related]
50. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
Ji M; Jang S; Lee JH; Seo EJ
Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
[No Abstract] [Full Text] [Related]
51. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
Chang H; Sloan S; Li D; Keith Stewart A
Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
[TBL] [Abstract][Full Text] [Related]
52. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Vikova V; Jourdan M; Robert N; Requirand G; Boireau S; Bruyer A; Vincent L; Cartron G; Klein B; Elemento O; Kassambara A; Moreaux J
Theranostics; 2019; 9(2):540-553. PubMed ID: 30809292
[TBL] [Abstract][Full Text] [Related]
54. Molecular pathogenesis of multiple myeloma.
Tonon G
Hematol Oncol Clin North Am; 2007 Dec; 21(6):985-1006, vii. PubMed ID: 17996585
[TBL] [Abstract][Full Text] [Related]
55. Next-generation-sequencing-based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemia.
Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Fischer U; Dugas M; Hu J; Borkhardt A
Genes Chromosomes Cancer; 2013 Jun; 52(6):564-79. PubMed ID: 23508829
[TBL] [Abstract][Full Text] [Related]
56. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.
Kazandjian D; Hill E; Hultcrantz M; Rustad EH; Yellapantula V; Akhlaghi T; Korde N; Mailankody S; Dew A; Papaemmanuil E; Maric I; Kwok M; Landgren O
Blood Cancer J; 2019 Feb; 9(2):15. PubMed ID: 30718460
[TBL] [Abstract][Full Text] [Related]
57. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.
Cremer FW; Bila J; Buck I; Kartal M; Hose D; Ittrich C; Benner A; Raab MS; Theil AC; Moos M; Goldschmidt H; Bartram CR; Jauch A
Genes Chromosomes Cancer; 2005 Oct; 44(2):194-203. PubMed ID: 16001433
[TBL] [Abstract][Full Text] [Related]
58. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
Walker BA; Wardell CP; Melchor L; Hulkki S; Potter NE; Johnson DC; Fenwick K; Kozarewa I; Gonzalez D; Lord CJ; Ashworth A; Davies FE; Morgan GJ
Blood; 2012 Aug; 120(5):1077-86. PubMed ID: 22573403
[TBL] [Abstract][Full Text] [Related]
59. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
[TBL] [Abstract][Full Text] [Related]
60. NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm.
Weinhold N; Moreaux J; Raab MS; Hose D; Hielscher T; Benner A; Meissner T; Ehrbrecht E; Brough M; Jauch A; Goldschmidt H; Klein B; Moos M
Genes Chromosomes Cancer; 2010 Apr; 49(4):333-41. PubMed ID: 20073075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]